PRM signs cancer deal

Intronn (Durham, N.C.), the U.S. subsidiary of Proteome Sciences (LSE:PRM), will use its SMaRT technology for spliceosome mediated mRNA trans-splicing under a CRADA with the National Cancer Institute ...